ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019
Optimizing glycemic control in type 2 diabetic patients through the use of a low-carbohydrate, high-fat, ketogenic diet: a review of two patients in primary care.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Efficacy of Low-Carbohydrate Ketogenic Diet in the Treatment of Type 2 Diabetes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Established guidelines continue to promote carbohydrate-rich (>130 g/day) diets in the primary-care management of type 2 diabetic (DM2) patients. A growing body of evidence suggests that a low-carbohydrate, high-fat, ketogenic diet (KD) may be a more effective nutritional strategy for improving glycemic control. Two diabetic patients, a 65-year-old female and a 52-year-old male, were placed on KDs consisting of 70% fat, 20%-25% protein, and 5%-10% carbohydrates and monitored for 12 weeks. The 65-year-old female demonstrated a 2.4% reduction in HBA1C over 12 weeks while reducing her diabetic medication by 75%. The 52-year-old male demonstrated a 2.5% reduction in HBA1C while eliminating all diabetic medications. These cases demonstrate the efficacy of KDs in terms of improving glycemic control in DM2 patients and lend support to the increased use of KDs in this population cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.